Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
The results of a large retrospective analysis noted significant age-related differences in the germline landscape of endometrial cancer. This study was presented as a poster at the 2025 American Society of...
A phase 2 study evaluating the safety and efficacy of letrozole, abemaciclib, and metformin in treating estrogen receptor–positive recurrent endometrial cancer highlights promising outcomes in a select...
A post hoc analysis of the DUO-E trial evaluated how durvalumab and maintenance olaparib influenced circulating tumor DNA dynamics in first-line endometrial cancer treatment.
A retrospective analysis presented at the American Society of Clinical Oncology 2025 Annual Meeting suggests that higher tumor mutational burden (TMB) may be linked to longer progression-free survival in...
The 2025 American Society of Clinical Oncology guideline update redefines the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer. Building on evidence from major trials, the update...
The latest OVATION-2 trial update, presented at the American Society of Clinical Oncology 2025 annual meeting, shows that adding intraperitoneal IMNN-001 to standard neoadjuvant chemotherapy improved both...
A phase II trial evaluating pembrolizumab plus lenvatinib in clear cell ovarian carcinoma shows promising response rates and 6-month progression-free survival.
A retrospective analysis from Memorial Sloan Kettering links higher patient-reported pain to increased emergency department utilization among individuals newly diagnosed with ovarian cancer. This study was...
